SEC Filings

Form 8-K
MOMENTA PHARMACEUTICALS INC filed this Form 8-K on 02/22/2019
Document Outline
Entire Document (193.5 KB)
Subdocument 1 - 8-K - 8-K
Page 1 - UNITED STATES
Page 2 - Item 2.02. Results of Operations and Financial Condition.
Page 3 - SIGNATURES
Subdocument 2 - EX-99.1 - EX-99.1
Page 1 - Exhibit 99.1
Page 2 - M230 (CSL730): a recombinant Fc multimer being developed in collaboration with CSL
Page 3 - Operating Expenses: Total GAAP operating expenses were $52.5 million in the fourth quarter of 2018.
Page 4 - Conference Call Information
Page 5 - N/A
Page 6 - MOMENTA PHARMACEUTICALS, INC.
Page 7 - MOMENTA PHARMACEUTICALS, INC.
Page 8 - MOMENTA PHARMACEUTICALS, INC.